ResearcherJohns Hopkins UniversityNo recent work listed
Gabriel D. Ivey
Matched on ORCID iD 0000-0002-5287-9278; OpenAlex author ID A5059084078. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2022: 2 papers
Papers 2
- Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
- Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher R. Shubert · 2 shared papers, 2022 · strength 0.25
- Paper Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenoc… DOI 10.1007/s00268-022-06667-x↗
- Paper Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical … DOI 10.1158/1078-0432.ccr-21-4165↗
- Jin Peng He · 2 shared papers, 2022 · strength 0.25
- Paper Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenoc… DOI 10.1007/s00268-022-06667-x↗
- Paper Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical … DOI 10.1158/1078-0432.ccr-21-4165↗
- William R. Burns · 2 shared papers, 2022 · strength 0.25
- Paper Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenoc… DOI 10.1007/s00268-022-06667-x↗
- Paper Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical … DOI 10.1158/1078-0432.ccr-21-4165↗
- Kelly J. Lafaro · 2 shared papers, 2022 · strength 0.25
- Paper Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenoc… DOI 10.1007/s00268-022-06667-x↗
- Paper Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical … DOI 10.1158/1078-0432.ccr-21-4165↗
- Richard Andrew Burkhart · 2 shared papers, 2022 · strength 0.25
- Paper Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenoc… DOI 10.1007/s00268-022-06667-x↗
- Paper Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical … DOI 10.1158/1078-0432.ccr-21-4165↗
- Lei Zheng · 2 shared papers, 2022 · strength 0.25
- Paper Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenoc… DOI 10.1007/s00268-022-06667-x↗
- Paper Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical … DOI 10.1158/1078-0432.ccr-21-4165↗
- Elizabeth Thompson · 1 shared paper, 2022 · strength 0.13
- Daniel Delitto · 1 shared paper, 2022 · strength 0.13
- Sami Shoucair · 1 shared paper, 2022 · strength 0.13
- Joseph R. Habib · 1 shared paper, 2022 · strength 0.13
- Benedict Kinny‐Köster · 1 shared paper, 2022 · strength 0.13
- Christopher Lee Wolfgang · 1 shared paper, 2022 · strength 0.13
- Amol Kumar Narang · 1 shared paper, 2022 · strength 0.13
- David Tsai Ting · 1 shared paper, 2022 · strength 0.12
- Theodore Sunki Hong · 1 shared paper, 2022 · strength 0.12
- Toni T. Seppälä · 1 shared paper, 2022 · strength 0.12
- Christopher L. Wolfgang · 1 shared paper, 2022 · strength 0.12
- Reecha Suri · 1 shared paper, 2022 · strength 0.12
- David P. Ryan · 1 shared paper, 2022 · strength 0.12
- Alec C. Kimmelman · 1 shared paper, 2022 · strength 0.12
- Elizabeth M. Jaffee · 1 shared paper, 2022 · strength 0.12
- David Arthur Tuveson · 1 shared paper, 2022 · strength 0.12
- Jacquelyn W. Zimmerman · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.